MedWatch

Veloxis Chairman wanted a commercial profile

According to Veloxis’ Chairman of the Board, Mette Kirstine Agger, Bill Polvino was not fired as CEO; the company simply needed to make a change to build the foundation for its commercial efforts in the US.

Veloxis’ management group simply needed more commercial strength to get US sales of its drug product Envarsus up and running. That was the relatively simple conclusion the company’s Board of Directors had reached and the reason why it said last week that CEO Bill Polvino would resign with immediate effect to make way for Craig Collard, says Chairman Mette Kirstine Agger.

“We are now launching Envarsus in the US, meaning we have a biotech company that goes from being a development company in the classic biotech sense to becoming a commercial company with its own commercialization in the US. When we bring in Craig Collard now, it’s because Craig has solid commercial and strategic experience with gearing up for a launch, carrying it out, and building a company from there. Bigger pharma outfits have the organization to launch, but in a small biotech company it’s something you have to build. Craig has been commercial his whole life and it’s where he has his strengths,” Metter Kirstine Agger tells MedWatch, adding:

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Biontech-direktører: Derfor måtte Afrika vente på coronavacciner

Tyske Biontech vil bruge de mange corona-milliarder på at hjælpe lande i Afrika med at komme både coronavirus, malaria og turberkulose til livs, men alligevel stod kontinentet langt nede i køen, da de første coronavacciner skulle distribueres. MedWatch har spurgt hvorfor.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier